Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 12:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: BTG International Inc. Clear all
Completed Not applicable Interventional Results available

Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres

NCT03052049
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Prostate Artery Embolization
Device
Lead sponsor
Northwestern University
Other
Eligibility
45 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 4, 2026, 12:46 PM EDT
Completed Early Phase 1 Interventional

Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma

NCT03960177
View directory record Official record
Conditions
Osteosarcoma
Interventions
Glucarpidase, Quality-of-Life Assessment
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
25 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Jacksonville, Florida • Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 4, 2026, 12:46 PM EDT
Completed Phase 2 Interventional Results available

TheraSphere for the Treatment of Liver Metastases

NCT00511862
View directory record Official record
Conditions
Colorectal Cancer, Carcinoma, Neuroendocrine, Neoplasm Metastasis
Interventions
Yttrium 90 glass microspheres
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 4, 2026, 12:46 PM EDT
Approved For Marketing No phase listed Expanded access

A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma

NCT01076517
View directory record Official record
Conditions
Liver Cancer
Interventions
Therasphere
Device
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 4, 2026, 12:46 PM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of Digibind for Treatment of Severe Preeclampsia

NCT00158743
View directory record Official record
Conditions
Pre-eclampsia
Interventions
Anti-digoxin antibody (FAB fragment), sodium chloride
Drug · Other
Lead sponsor
BTG International Inc.
Other
Eligibility
Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Mobile, Alabama • Phoenix, Arizona • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 4, 2026, 12:46 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets

NCT01581307
View directory record Official record
Conditions
Liver Cancer, Pancreatic Cancer
Interventions
FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin), TheraSpheres
Drug · Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 4, 2026, 12:46 PM EDT
Completed Not applicable Interventional Results available

Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma

NCT01253148
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
TheraSphere® Yttrium-90 (Y-90) Microspheres
Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 4, 2026, 12:46 PM EDT
Withdrawn Early Phase 1 Interventional

Ga-68 MAA Distribution in PAE Patients

NCT04243824
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Gallium 68 Macro-aggregated albumin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 4, 2026, 12:46 PM EDT
No Longer Available No phase listed Expanded access

Therasphere for Unresectable Primary or Secondary Liver Neoplasia

NCT02960620
View directory record Official record
Conditions
Liver Cancer, Liver Neoplasms, HepatoCellular Carcinoma
Interventions
TheraSphere Treatment
Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 4, 2026, 12:46 PM EDT
Completed Phase 4 Interventional Results available

Randomized, Double-Blind, Placebo-Controlled Study: CroFab® vs Placebo for Copperhead Snake Envenomation

NCT01864200
View directory record Official record
Conditions
Snake Bites
Interventions
Crotalidae polyvalent immune fab (ovine), Placebo
Biological
Lead sponsor
BTG International Inc.
Other
Eligibility
12 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
18
States / cities
Augusta, Georgia • Kansas City, Kansas • St Louis, Missouri + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Oct 4, 2026, 12:46 PM EDT
Terminated Not applicable Interventional Results available

A Study to Assess the Effect of Y-90 Therapy on Non-target/Background Liver

NCT02966223
View directory record Official record
Conditions
HCC, Liver Cancer
Interventions
MRI and HIDA scan
Radiation
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 4, 2026, 12:46 PM EDT
Completed Not applicable Interventional Results available

LC Bead LUMI for Prostatic Artery Embolization

NCT03372096
View directory record Official record
Conditions
BPH
Interventions
Prostatic Artery Embolization
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Woodbridge, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 4, 2026, 12:46 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetic Study of Polidocanol Endovenous Microfoam (PEM)

NCT01428076
View directory record Official record
Conditions
Varicose Veins
Interventions
Polidocanol Endovenous Microfoam (PEM)
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 4, 2026, 12:46 PM EDT
Completed No phase listed Observational

Retrospective Evaluation of CroFab - Efficacy in Severe Envenomation

NCT00927381
View directory record Official record
Conditions
Snake Envenomation
Interventions
Not listed
Lead sponsor
BTG International Inc.
Other
Eligibility
Not listed
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 4, 2026, 12:46 PM EDT
Completed No phase listed Observational

Copperhead Envenomation Observational Study

NCT01651299
View directory record Official record
Conditions
Copperhead Snake Envenomation
Interventions
Not listed
Lead sponsor
BTG International Inc.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Lexington, Kentucky • Shreveport, Louisiana • Jackson, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Oct 4, 2026, 12:46 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

NCT03457948
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Neuroendocrine Neoplasm
Interventions
Arterial Embolization, Pembrolizumab, Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate, Yttrium-90 Microsphere Radioembolization
Procedure · Biological · Device
Lead sponsor
Nicholas Fidelman, MD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 4, 2026, 12:46 PM EDT
Approved For Marketing No phase listed Expanded access

TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma

NCT00906984
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Primary Liver Cancer
Interventions
TheraSphere
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 4, 2026, 12:46 PM EDT
Withdrawn Phase 4 Interventional

Effect of PEM Treatment of Superficial Axial and Tributary Vein Reflux on Improvement of Wound Healing in VLUs

NCT02988063
View directory record Official record
Conditions
Leg Ulcer, Veins, Varicose, Venous Ulcer, Reflux, Venous Reflux, Venous Leg Ulcer, Varicose Veins, Varicose Ulcer, Varicose Veins Leg
Interventions
Polidocanol Endovenous Microfoam (PEM)
Drug
Lead sponsor
OhioHealth
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 4, 2026, 12:46 PM EDT
Completed Phase 1 Interventional

Tc99m-MAA Bronchial Artery Injection During Bronchial Embolization for Pulmonary Mass Induced Hemoptysis for Dosimetry Planning

NCT04105283
View directory record Official record
Conditions
Lung Cancer
Interventions
Tc99m-MAA
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 4, 2026, 12:46 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®

NCT03203837
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Plasma collection
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 4, 2026, 12:46 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Voraxaze for Delayed Methotrexate Clearance

NCT00424645
View directory record Official record
Conditions
Hematologic Malignancy, Solid Tumor
Interventions
Voraxaze (Glucarpidase), Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 4, 2026, 12:46 PM EDT
Withdrawn Not applicable Interventional

Pelvic Pain Treated With MR-guided Cryoanalgesia

NCT04046406
View directory record Official record
Conditions
Pelvic Pain Syndrome, Groin Pain, Meralgia Paresthetica, Low Back Pain, Perineal Neuralgia
Interventions
MR neurography-guided cryoanalgesia
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 4, 2026, 12:46 PM EDT
Completed Phase 1 Interventional Results available

Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze

NCT00634504
View directory record Official record
Conditions
Osteosarcoma, Leukemia, Lymphoma
Interventions
glucarpidase, high-dose methotrexate, leucovorin, high-dose methotrexate, leucovorin
Drug
Lead sponsor
BTG International Inc.
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 4, 2026, 12:46 PM EDT
Terminated Not applicable Interventional Results available

Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia

NCT03059030
View directory record Official record
Conditions
Thrombocytopenia, Cirrhosis
Interventions
TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 4, 2026, 12:46 PM EDT